The patent, which was issued on Feb. 4, covers the various components, purpose and simulation methodology of the surgical training device, and credits the company’s CEO and founder, Dr. Christopher Sakezles, with its design.
The Central Line Simulation and Training Device includes an upper torso made with the company’s life-like, proprietary SynTissue®. It has underlying vascular features, like the carotid artery, superior vena cava, subclavian and jugular veins. When deployed, the trainer is paired with a tablet-powered wireless pump that controls both arterial and venous blood flow.
Surgical residents can use the device to practice techniques associated with central venous catheterization, a routine minimally invasive procedure typically performed in the radiology department using x-ray and ultrasound guidance. Improper placement of a central venous access line has been associated with a wide variety of health complications, including air embolism, cava perforation, infection and more.
According to SynDaver, those in the medical field who can benefit from practicing on the device include medical residents who hope to become general surgeons and interventional radiologists.
The patent is the third awarded to SynDaver since July and their 16th to date. In 2019, the Tampa-headquartered company received federal patent protection for the technology behind two of its products, a Wearable Chest Tube Skills Trainer, as well as its Cricothyroidotomy and Nasogastric Tube medical simulation trainer.
SynDaver’s leadership has continued to emphasize the company’s history of creating innovative medical simulation technologies, as well as the need to continue pioneering new solutions within the medical field.
“Many procedures performed in the medical field require repetitive practice to ensure the high level of skill required to improve patient outcomes. At SynDaver, we always strive to develop new technologies and tools that create the most realistic simulation experiences possible and to instill in medical students and practitioners the confidence and expertise they need to perform in a real-world setting,” said Sakezles.
Like many of SynDaver’s products, the central line trainer is compatible with all known imaging techniques and is able to produce realistic imaging under pulse flow Doppler ultrasound due to the simulation of natural blood flow conditions; exhibiting pulsatile blood flow in the arterial vessel and drainage blood flow in the venous vessel.
SynDaver’s synthetic humans, animals and task trainers simulate detailed anatomy of live patients, including individual muscles, tendons, veins, arteries, nerves and organ systems. The company’s proprietary SynTissue® synthetic tissues are made of water, fibers and salts. Each of these non-toxic, non-latex tissues has been validated against the relevant living tissue for mechanical and physical properties.
For more information about SynDaver or the company’s products, visit https://syndaver.com/.
About SynDaver
Headquartered in Tampa, SynDaver is the world’s leading manufacturer of hyper-realistic, synthetic human and animal models for medical education, training and surgical simulation. SynDaver’s synthetic bodies mimic live tissue properties and are used by high schools, colleges and universities, hospitals, medical device companies and the military for training, testing and validation. SynDaver has the world’s largest database of live-tissue properties. Made from a proprietary formula of water, salts and fibers, the company holds 16 patents on their materials, processes and the related products. SynDaver has more than 100 employees at its facilities in the U.S. and is planning additional facilities in Europe, China, Brazil and India. SynDaver products have been lauded by industry experts and earned a cult following after appearances on ABC’s Shark Tank, MythBusters, Grey’s Anatomy and the series finale of CSI. For more information on SynDaver or their product offerings, visit http://SynDaver.com.
For media-related inquiries, please contact our PR firm at 813.279.8335 or by emailing news@judgepr.com.
